Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Isolation of Hymenolepis diminuta Cysticercoids for therapeutic use: The need for open-source methodology
ABSTRACT
Background:
Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting.
Objective:
This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Hymenolepis diminuta (HDCs), a process that has not been described previously but that would be necessary before HDCs can be used clinically.
Methods:
The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device.
Results:
The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm2, dependent in large part upon the host. That cross-sectional area correlated in a linear fashion with the steady-state speed of HDCs while falling through solution, which varied over a 5-fold range, from approximately 0.4 mm/s to 2.0 mm/s in the solution tested. These parameters were used to develop a washing device that utilized a variable flow speed dictated by changing column diameter and an upward flowing column of liquid that effectively and simultaneously suspended HDCs of various sizes in a wash solution.
Conclusions:
This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics. Clinical Trial: Not applicable
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.